NCT05238844 - A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

May 25, 2022

Study Completion Date

May 25, 2022

Conditions

Chronic Hepatitis b

Interventions

DRUG

ATI-2173 25mg

ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.

DRUG

Vebicorvir 300mg

Vebicorvir (formerly ABI-H0731) is an orally administered, potent and selective small molecule inhibitor of the HBV core protein

DRUG

Viread 300Mg Tablet

Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.

Trial Locations (2)

Unknown

"Republican Clinical Hospital Timofei Mosneaga Arensia EM Unit", Chisinau

"Medical Center of Limited Liability Company Harmoniya krasy", Kyiv